1 in 9 Americans Now on GLP-1s
A recent Gallup poll shows that the use of GLP-1 drugs in the US has surged to a record high, with 11% of US adults currently using these medications and 15% reporting having used them at some point…
Read the full articleYou might also wanna read
GLP-1 Drug Use Triples In Two Years As American Obesity Rate Falls, Gallup Finds
A new Gallup survey reveals that 11% of U.S. adults currently take GLP-1 medications for weight loss, a sharp rise from just 3% in 2024. The
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Obesity in retreat as GLP-1 use nearly quadruples: New data paints a different picture for manufacturers
US obesity has fallen for the first time in decades while GLP-1 use has reached record levels, echoing signs of a broader slowdown across se
Obesity in retreat as GLP-1 use nearly quadruples: New data paints a different picture for manufacturers
US obesity has fallen for the first time in decades while GLP-1 use has reached record levels, echoing signs of a broader slowdown across se
An online secret shopping study reveals easy access to GLP-1 prescriptions with limited clinician oversight
A Yale research team found that 92% of sites prescribed the GLP medication and 69% mailed it with little to no clinician oversight.
An online secret shopping study reveals easy access to GLP-1 prescriptions with limited clinician oversight
A Yale research team found that 92% of sites prescribed the GLP medication and 69% mailed it with little to no clinician oversight.
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.
gizmodo.com·1mo ago
GLP-1 Prescriptions Surge Sevenfold Among Women With PCOS: What to Know About Off-Label Use
Wondering how GLP-1 drugs like Wegovy, Zepbound and Munjaro, work for people with PCOS? Here’s what you need to know.
pcosnutrition.com·4d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.